Quantifying metamorphopsia in patients with diabetic macular oedema and other macular abnormalities

Asaf Achiron*, Oded Lagstein, Mirit Glick, Zvi Gur, Elisha Bartov, Zvia Burgansky-Eliash

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review


Purpose To quantify subjective visual metamorphopsia in newly diagnosed patients suffering from diabetic macular oedema (DME) and other macular abnormalities and to evaluate anti-VEGF treatment effect. Methods Patients with DME, subfoveal choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD) or retinal venous occlusion (RVO) were recruited. Metamorphopsia score (Mscore) was calculated using M-Charts at baseline and at the end of a series of anti-VEGF injections. Results Fifteen eyes of 10 patients with DME, 14 eyes of 13 patients with AMD-CNV and five patients with RVO were included in this study. At baseline, positive Mscore was observed in 46.6% of eyes with DME, 50% of eyes with AMD-CNV and four of five eyes with RVO. Treatment led to a complete metamorphopsia reduction (Mscore = 0) in 71.4% of DME patients, 35.7% of AMD and 0% of RVO patients. Conclusion We suggest that the M-charts may serve as an additional test for diagnosis and follow-up, complementary to morphological evaluation by imaging, in diabetic patients facing their first anti-VEGF treatment.

Original languageEnglish
Pages (from-to)e649-e653
JournalActa Ophthalmologica
Issue number8
StatePublished - 1 Dec 2015


  • Anti-VEGF
  • M-chart
  • diabetic retinopathy
  • macular oedema
  • metamorphopsia
  • quantification


Dive into the research topics of 'Quantifying metamorphopsia in patients with diabetic macular oedema and other macular abnormalities'. Together they form a unique fingerprint.

Cite this